377 related articles for article (PubMed ID: 16158069)
41. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
42. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
[TBL] [Abstract][Full Text] [Related]
43. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
[TBL] [Abstract][Full Text] [Related]
44. Moxifloxacin-induced torsades de pointes.
Sherazi S; DiSalle M; Daubert JP; Shah AH
Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
[TBL] [Abstract][Full Text] [Related]
45. Electrocardiographic method for identifying drug-induced repolarization abnormalities associated with a reduction of the rapidly activating delayed rectifier potassium current.
Couderc JP; Vaglio M; Xia X; McNitt S; Hyrien O
Conf Proc IEEE Eng Med Biol Soc; 2006; 2006():4010-5. PubMed ID: 17946595
[TBL] [Abstract][Full Text] [Related]
46. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
Briasoulis A; Agarwal V; Pierce WJ
Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
[TBL] [Abstract][Full Text] [Related]
47. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
[TBL] [Abstract][Full Text] [Related]
48. Use of arterially perfused rabbit ventricular wedge in predicting arrhythmogenic potentials of drugs.
Chen X; Cordes JS; Bradley JA; Sun Z; Zhou J
J Pharmacol Toxicol Methods; 2006; 54(3):261-72. PubMed ID: 16564186
[TBL] [Abstract][Full Text] [Related]
49. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
Alexandrou AJ; Duncan RS; Sullivan A; Hancox JC; Leishman DJ; Witchel HJ; Leaney JL
Br J Pharmacol; 2006 Apr; 147(8):905-16. PubMed ID: 16474415
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.
Dubois VF; Casarotto E; Danhof M; Della Pasqua O
Br J Pharmacol; 2016 Oct; 173(19):2819-32. PubMed ID: 27427789
[TBL] [Abstract][Full Text] [Related]
51. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve.
Vormberge T; Hoffmann M; Himmel H
J Pharmacol Toxicol Methods; 2006; 54(2):130-40. PubMed ID: 16757186
[TBL] [Abstract][Full Text] [Related]
52. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
53. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.
Bloomfield DM; Kost JT; Ghosh K; Hreniuk D; Hickey LA; Guitierrez MJ; Gottesdiener K; Wagner JA
Clin Pharmacol Ther; 2008 Oct; 84(4):475-80. PubMed ID: 19238652
[TBL] [Abstract][Full Text] [Related]
54. Validation of the normal, freely moving Göttingen minipig for pharmacological safety testing.
Markert M; Stubhan M; Mayer K; Trautmann T; Klumpp A; Schuler-Metz A; Schumacher K; Guth B
J Pharmacol Toxicol Methods; 2009; 60(1):79-87. PubMed ID: 19427912
[TBL] [Abstract][Full Text] [Related]
55. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
[TBL] [Abstract][Full Text] [Related]
56. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.
Nalos L; Varkevisser R; Jonsson MK; Houtman MJ; Beekman JD; van der Nagel R; Thomsen MB; Duker G; Sartipy P; de Boer TP; Peschar M; Rook MB; van Veen TA; van der Heyden MA; Vos MA
Br J Pharmacol; 2012 Jan; 165(2):467-78. PubMed ID: 21718297
[TBL] [Abstract][Full Text] [Related]
58. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
[TBL] [Abstract][Full Text] [Related]
59. Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
Kimura K; Tabo M; Itoh M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
J Toxicol Sci; 2007 Aug; 32(3):217-30. PubMed ID: 17785939
[TBL] [Abstract][Full Text] [Related]
60. Investigation of parameters highlighting drug induced small changes of the T-wave's morphology for drug safety studies.
Baas T; Gräfe K; Khawaja A; Dössel O
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():3796-9. PubMed ID: 22255166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
